LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

Kodu・Aktsiate loetelu・MacroGenics Inc

MacroGenics Inc

Suletud

SektorTervishoid

2.76 -5.8

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.73

Max

2.93

Põhinäitajad
By Trading Economics
Sissetulek	-31M -14M
Müük	-32M 41M
Aktsiakasum	-0.22
Kasumimarginaal	-34.333
Töötajad	293
EBITDA	-37M -15M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+36.52% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	63M 186M
Eelmine avamishind	8.56
Eelmine sulgemishind	2.76

Uudiste sentiment

By Acuity

31%

69%

103 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

1.47 / 1.64 Toetus ja vastupanu

MacroGenics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. märts 2026, 23:15 UTC

Uudisväärsed sündmused

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30. märts 2026, 22:36 UTC

Uudisväärsed sündmused

Australian Government Rules Out Boots on the Ground in the Middle East

30. märts 2026, 22:13 UTC

Omandamised, ülevõtmised, äriostud

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30. märts 2026, 21:00 UTC

Tulu

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30. märts 2026, 20:15 UTC

Uudisväärsed sündmused

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30. märts 2026, 23:40 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. märts 2026, 23:40 UTC

Market Talk

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30. märts 2026, 23:36 UTC

Market Talk

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30. märts 2026, 23:12 UTC

Market Talk

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30. märts 2026, 22:49 UTC

Market Talk

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30. märts 2026, 22:44 UTC

Market Talk

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30. märts 2026, 22:43 UTC

Market Talk

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30. märts 2026, 22:42 UTC

Market Talk

South32 Should Go for Growth, Says New Bull -- Market Talk

30. märts 2026, 22:18 UTC

Market Talk

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30. märts 2026, 22:05 UTC

Market Talk

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30. märts 2026, 21:58 UTC

Omandamised, ülevõtmised, äriostud

Sun Life Financial Agrees to Buy Bell Partners for $350M

30. märts 2026, 21:39 UTC

Omandamised, ülevõtmised, äriostud

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30. märts 2026, 21:38 UTC

Omandamised, ülevõtmised, äriostud

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30. märts 2026, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30. märts 2026, 21:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. märts 2026, 21:25 UTC

Market Talk

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30. märts 2026, 21:03 UTC

Omandamised, ülevõtmised, äriostud

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30. märts 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30. märts 2026, 20:09 UTC

Tulu

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30. märts 2026, 20:00 UTC

Uudisväärsed sündmused

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Võrdlus sarnastega

Hinnamuutus

MacroGenics Inc Prognoos

Hinnasiht

By TipRanks

36.52% tõus

12 kuu keskmine prognoos

Keskmine 4 USD 36.52%

Kõrge 4 USD

Madal 4 USD

Põhineb 3 Wall Streeti analüütiku instrumendi MacroGenics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi MacroGenics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.47 / 1.64Toetus ja vastupanu

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

103 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.